BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TORL Biotherapeutics\, LLC readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies TORL Biotherapeutics\, LLC's drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06690775-2773@assetmemo.bio
DTSTAMP:20261121T005936Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ixotatug vedotin: Phase 2 readout est. (NCT06690775)
DESCRIPTION:Ixotatug vedotin\, phase 2\, Ovarian Cancer.\nStudy: CATALINA-2
 : A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.\nEst
 imated primary completion: October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ixotatug-vedotin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06690775
URL:https://assetmemo.bio/drug/ixotatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322094-2773@assetmemo.bio
DTSTAMP:20261121T005936Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ixotatug vedotin: Phase 1/2 readout est. (NCT07322094)
DESCRIPTION:Ixotatug vedotin\, phase 1/2\, Ovarian Cancer.\nStudy: CATALINA
 -4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemo
 therapy Given Before Initial Surgery in Women With Advanced Stage Ovarian 
 Cancer\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ixotatug-vedotin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07322094
URL:https://assetmemo.bio/drug/ixotatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
